menu
    • menu

    Company profile for Novartis Pharmaceuticals Corporation

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals ...
    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals Corporation, we believe that all Americans deserve access to quality health care, including prescription medicines, health education about their disease or condition

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Novartis Pharmaceuticals CorporationSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Klybeckstrasse 141, CH-4057, Basel
    Telephone
    Telephone
    +41 61 324 11 11
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novartis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI WW Frankfurt

    Not Confirmed

    envelop Contact Supplier

    CPhI WW Frankfurt

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    "50 Years of Innovation: Mikart

    mic"50 Years of Innovation: Mikart's legacy and what's next in CDMO excellence"

    This week, SpeakPharma interviews Michael Kallelis, CEO of Mikart, a leading contract development and manufacturing organization (CDMO) celebrating its 50th anniversary in the pharmaceutical industry. Based in the United States, Mikart has built a reputation for technical expertise, flexible business terms, and specialized capabilities in pharmaceutical development services. In this exclusive interview, Kallelis discusses how Mikart maintains its competitive edge through its Pharmaceutical Development Services team, quality control framework, and commitment to customized business solutions. Kallelis also explores the company's focus on liquid suspensions manufacturing, driven by growing demand from aging populations and pediatric patients, and explains how Mikart balances traditional family business values with modern innovation. HIGHLIGHTS// celebrating its 50th anniversary/ reputation for technical expertise/ how Mikart maintains its competitive edge Mikart is celebrating 50 years in business this year — what are some of the major milestones that have shaped the company's journey?  Over our 50-year history, we've celebrated many memorable milestones, but one of the most significant in recent years has been achieving our growth objectives. This success was driven by the strategic expansion of our Pharmaceutical Development Services team, the completion of full aggregate serialization in our packaging department, modernization of our IT systems, enhanced productivity, and our ability to attract both new and returning customers. HIGHLIGHTS// expansion of our Pharmaceutical Development Services team/ completion of full aggregate serialization/ attract both new and returning customers How has Mikart maintained its competitive edge in a constantly evolving pharmaceutical landscape? Our customers consistently tell us that what sets us apart is our technical expertise, high service level, and flexible, customized business terms. At the core of our competitiveness is our focus on Pharmaceutical Development Services (PDS). Mikart's PDS opinion leaders are actively engaged in business development and form early, collaborative relationships with our customers' technical teams. From the outset, our prospects and clients work directly with Mikart's experienced formulation chemists, analytical method developers, and process-oriented engineers to design robust, reproducible, and efficient processes. This hands-on development approach is supported by a comprehensive quality control testing framework — covering raw material testing, in-process checks, on-site microbiological testing, and in-house stability studies. Oversight is provided by our robust Quality Management System, managed by a dedicated Quality Assurance and Regulatory Affairs team. The result is disciplined problem-solving, timely FDA submissions, and a "right-first-time" philosophy that accelerates time-to-market. We operate with a strong sense of urgency and consistently deliver a high level of customer satisfaction. What truly differentiates Mikart is our commitment to customized business terms that eliminate common roadblocks seen with other CDMOs. Our secret sauce is our exceptional service and flexibility in helping our customers bring innovative medicines to patients. HIGHLIGHTS// technical expertise, high service level/ flexible, customized business terms/ comprehensive quality control testing framework/ dedicated Quality Assurance and Regulatory Affairs team/ timely FDA submissions/ accelerates time-to-market What capabilities or services does Mikart offer today that didn't exist 10 or 20 years ago? Mikart was an early leader in serialization, implementing full capabilities well ahead of the industry timeline. This proactive approach has kept our packaging team in high demand. We also upgraded our tablet compression equipment to enhance both speed and reliability. To support growing development needs, we invested in new lab-scale development equipment, unit dose cup filling, sachet packaging, low-humidity suites, and a brand-new suite dedicated to closed-system manufacturing of liquids and suspensions. Most recently, we launched a multi-million dollar expansion of our packaging lines to support higher-speed tablet filling, powder-in-bottle formats, and new liquid fill capabilities. HIGHLIGHTS// early leader in serialization/ upgraded our tablet compression equipment/ multi-million dollar expansion of our packaging lines Why are liquid suspensions becoming such a key focus, and how is Mikart positioned? Formulating suspensions is a complex process that requires specialized expertise and equipment. According to our customers, few mid-market CDMOs do it well — and Mikart is one of them. There is growing industry demand for high-quality suspension manufacturing, driven by the needs of the aging baby boomer population and pediatric patients. For both groups, swallowing tablets or capsules can be difficult, making oral liquid suspensions a more practical alternative. In addition to being easier to administer, suspensions offer pharmacological advantages and can improve dosing compliance. Enhanced flavoring techniques further improve the patient experience — especially for children and infants — by making medicines more palatable. HIGHLIGHTS// growing industry demand for high-quality suspension manufacturing/ suspensions offer pharmacological advantages/ improve dosing compliance How does Mikart balance tradition with innovation to meet modern customer demands?  At Mikart, we work hard to preserve the values of a traditional family business, even as we continue to modernize. Our goal is to make every customer feel like they are our top priority. Each customer is supported by a dedicated project manager who serves as their primary point of contact, along with direct access to key team members across departments. This structure ensures our customers are never isolated from our subject matter experts and can get timely, accurate answers to their questions. We're also mindful of the "technology trap" — the tendency to pursue every new innovation at the expense of focus and efficiency. Instead, we rely on market data and customer trends to guide our investments, enabling us to concentrate our resources and capital on technologies that meet real market needs. HIGHLIGHTS// customer is supported by a dedicated project manager/ customers are never isolated from our subject matter experts/ we rely on market data and customer trends to guide our investments/ meet real market needs Looking ahead, what's in store for Mikart in the next 5-10 years? Mikart's strategic plan is now in full motion, and with the momentum we've built, 50 percent growth is within reach. This projection is backed by a strong pipeline of annual FDA filings, a growing customer base, and a robust portfolio of active Pharmaceutical Development Services projects. As we grow, we remain committed to delivering exceptional service and continuously evolving to meet the changing needs of our customers. With renewed political emphasis on domestic manufacturing for the US market, we are ideally positioned to support the rapid, cost-effective development and production of high-quality medicines here at home. As we approach our 50th anniversary in the CDMO industry, we celebrate our legacy and look forward with optimism to the opportunities ahead in the next 5 to 10 years. HIGHLIGHTS// 50 percent growth is within reach/ strong pipeline of annual FDA filings 

    Impressions: 2724

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence

    PharmaCompass
    17 Jul 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaIngredients for Innovative FormulationsIngredients for Innovative Formulations

    Ingredients for Innovative Formulations
    Ingredients for Innovative Formulations

    reelIngredients for Innovative Formulations

    This PharmaReel highlights Kirsch Pharma’s expertise in providing premium quality raw materials, custom blends, and tailor-made solutions. With 40+ years of expertise and certified quality (GMP, ISO 9001, FSSC 22000, Halal, Kosher), Kirsch supports pharma, biotech, and nutrition industries worldwide.

    Impressions: 718

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    FDA approvals drop 24% in H1 2025; GSK’s UTI med, Vertex’s non-opioid painkiller lead pack of first-in-class meds

    FDA approvals drop 24% in H1 2025; GSK’s UTI med, Vertex’s non-opioid painkiller lead pack of first-in-class meds

    It has been a turbulent year for the US Food and Drug Administration (FDA), marked by reductions in both staff and budget, shake-ups at the top and a reduction in inspections. This upheaval has clearly impacted the functioning of the agency, with reports of missed deadlines and reduced responsiveness. This disruption resulted in a slowdown in new drug approvals in the first half of 2025 (H1 2025), as opposed to the same period last year. Incidentally, drug approvals in H1 2024 were also down by 19 percent compared to H1 2023. FDA’s Center for Drug Evaluation and Research (CDER) approved 16 novel drugs in H1 2025, down from 21 in H1 2024, a decline of nearly 24 percent. Of these, nine were small molecules and seven were biologics. The period saw eight first-in-class therapies get CDER’s approval, as opposed to 17 in H1 2024. FDA’s Center for Biologics Evaluation and Research (CBER) approved seven biologics in H1 2025, compared to eight in the same period last year. In comparison, both Health Canada and the European Medicines Agency (EMA) reported a strong rebound in approvals and authorizations, respectively. Health Canada approved 20 drugs in H1 2025, as opposed to 10 in H1 2024. Similarly, EMA authorized 19 new therapies in H1 2025, compared to 15 in H1 2024. Notably, EMA’s pending decisions increased to 25 in H1 2025, from 14 in the same period last year, while conditional authorizations remained static at five. This underscores EMA’s active regulatory pipeline, suggesting that more drugs could be approved in Europe soon.   View New Drug Approvals in H1 2025 with Estimated Sales (Free Excel Available) Vertex’s non-opioid painkiller, GSK’s antibiotic for UTI, Merck’s RSV antibody bag FDA nods Oncology remained the single largest category in H1 2025 with seven new drugs being approved by the FDA, followed by four rare diseases and disorders and as many infections and infective diseases.  The eight drugs that were designated first-in-class in H1 2025 are: Journavx (Suzetrigine), Imaavy (nipocalimab), Emrelis (telisotuzumab vedotin), Blujepa (gepotidacin mesylate), Qfitlia (fitusiran), Avmapki Fakzynja Co-Pack (avutometinib potassium/defactinib hydrochloride), Tryptyr (acoltremon), and Andembry (garadacimab). In January, a new class of non-opioid pain therapy made a debut — FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine). This first-in-class oral analgesic could bring in US$ 2.9 billion in sales for Vertex by 2030. The half year also saw a new oral antibiotic — GSK’s Blujepa (gepotidacin) — for treating uncomplicated urinary tract infections (uUTIs) bag FDA approval. This is the first new antibiotic for uUTIs in nearly three decades. It treats infections caused by resistant pathogens such as E. coli and K. pneumoniae. In June, Merck’s Enflonsia (clesrovimab), a long-acting monoclonal antibody, won FDA approval to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season. A single 105 mg dose provides protection for about five months, the length of a typical RSV season. Enflonsia could bring in US$844 million in annual sales by 2030.   View New Drug Approvals in H1 2025 with Estimated Sales (Free Excel Available)  FDA approves four meds for rare diseases, including SpringWorks’ Gomekli, Novartis’ Vanrafia In H1 2024, rare genetic diseases had witnessed some significant approvals. The trend continued in H1 2025. In February, Gomekli (mirdametinib), developed by SpringWorks Therapeutics, became the first approved therapy for neurofibromatosis type 1 (a genetic disorder that causes tumors to grow on nerve tissues) in adult and pediatric patients who have symptomatic plexiform neurofibromas (benign, complex nerve tumors) not amenable to complete resection. Analysts expect peak sales of around US$ 0.8 billion by 2030. Post this approval, SpringWorks got acquired by Merck KGaA for approximately US$ 3.9 billion. The same month, Ono Pharma-owned Deciphera’s Romvimza (vimseltinib) became the first oral therapy approved for another rare disease known as symptomatic tenosynovial giant cell tumor. This is a benign but aggressive growth that can be painful. This new drug offers patients an option beyond surgery. In March, Sanofi’s Qfitlia (fitusiran) was approved for routine prophylaxis in hemophilia A or B, with or without inhibitors. And in April, Novartis’ Vanrafia (atrasentan) was granted accelerated approval for IgA nephropathy (a chronic autoimmune kidney disease), which is at the risk of rapid progression. Vanrafia could bring in sales of over US$ 735 million by 2030. Johnson & Johnson secured approval for Imaavy (nipocalimab-aahu) for generalized myasthenia gravis (a chronic autoimmune disease that causes muscle weakness) in adults and adolescents. Imaavy’s sales could cross US$1.17 billion by 2030. Rare diseases continue to attract regulatory attention, with the trend carrying into the current quarter. July witnessed two noteworthy rare-disease approvals — Ekterly (garadacimab), CSL’s once-monthly prophylactic treatment for hereditary angioedema (a genetic disorder that causes recurrent episodes of swellings), and Sephience (pegvaliase-abcx), BioMarin’s new therapy for phenylketonuria (a rare metabolic disorder).   View New Drug Approvals in H1 2025 with Estimated Sales (Free Excel Available)  FDA greenlights new oncology therapies, including Astra’s Datroway, AbbVie’s Emrelis The field of oncology saw some notable new drug approvals. In January, Datroway (datopotamab deruxtecan), an antibody-drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo, was granted approval for adults with unresectable or metastatic, hormone receptor-positive, HER2-negative breast cancer. Later, in June, the FDA granted accelerated approval  to AstraZeneca;s Datroway for adults with locally advanced or metastatic, EGFR-mutated non-small cell lung cancer. The drug’s peak annual sales are projected at about US$ 4.2 billion by 2030. In May, Emrelis (telisotuzumab vedotin-tllv), AbbVie’s ADC was granted FDA’s accelerated approval. Emrelis treats locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) characterized by significantly increased levels of the c-Met protein in cancer cells. FDA also approved a companion diagnostic test — Roche's Ventana — in May to determine the c-Met protein biomarker status in order to identify patients eligible for Emrelis.  The same month, FDA also granted accelerated approval to Verastem’s Avmapki Fakzynja Co-pack, a dual oral therapy for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer (LGSOC). This novel regimen combines two inhibitors — avutometinib and defactinib — to disrupt critical signaling pathways that fuel tumor growth. In ophthalmology, Alcon re-entered the prescription pharmaceutical market with Tryptry (acoltremon), a first-in-class TRPM8 agonist for dry eye disease, which stimulates corneal nerves to increase tear production.   View New Drug Approvals in H1 2025 with Estimated Sales (Free Excel Available)  Our view The changes in the FDA are clearly having a far-reaching impact on the global pharmaceutical industry. There have been reports of drugmakers losing confidence in the FDA, which has been a gold standard for drug regulation. Some American biotechs are shifting early trials outside of the US. With EMA and Health Canada authorizing/approving a larger number of drugs in H1 2025, we do see some changes underway that may eventually reshape drug development.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4952

    https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds

    #PharmaFlow by PHARMACOMPASS
    28 Aug 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis to Acquire Tourmaline Bio for $1.4 Billion
    Novartis to Acquire Tourmaline Bio for $1.4 Billion

    09 Sep 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-acquire-tourmaline-bio-14-billion-2025-09-09/

    REUTERS
    09 Sep 2025
    Share Share
    NRG Secures £50M Series B Funding for Parkinson's Research
    NRG Secures £50M Series B Funding for Parkinson's Research

    08 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/08/3145831/0/en/NRG-Therapeutics-Announces-Oversubscribed-50m-67m-Series-B-Financing-to-Deliver-Clinical-Data-in-Parkinson-s-and-Proof-of-Concept-in-ALS-MND.html

    GLOBENEWSWIRE
    08 Sep 2025
    Share Share
    Novartis Signs up To $5.2 B Deal with China's Biotech Argo
    Novartis Signs up To $5.2 B Deal with China's Biotech Argo

    04 Sep 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-signs-up-52-billion-licensing-deal-with-chinas-biotech-argo-heart-drugs-2025-09-03/

    REUTERS
    04 Sep 2025
    Share Share
    Arrowhead, Novartis in Up to $2B Deal for Neuromuscular Therapy
    Arrowhead, Novartis in Up to $2B Deal for Neuromuscular Therapy

    03 Sep 2025

    // REUTERS

    https://www.reuters.com/sustainability/boards-policy-regulation/arrowhead-novartis-up-2-billion-deal-neuromuscular-therapy-license-2025-09-02/

    REUTERS
    03 Sep 2025
    Share Share
    Novartis Plans 58 Layoffs in N.J.
    Novartis Plans 58 Layoffs in N.J.

    02 Sep 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/novartis-plots-58-layoffs-new-jersey-amid-reviews-operations-us-hq

    FIERCE PHARMA
    02 Sep 2025
    Share Share
    Gateway to Growth: Innovation and Opportunity at the 8th CIIE
    Gateway to Growth: Innovation and Opportunity at the 8th CIIE

    01 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250901129755/en/Gateway-to-Growth-Innovation-and-Opportunity-at-the-8th-CIIE

    BUSINESSWIRE
    01 Sep 2025
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact AveXis Inc and get a quotation

    AveXis Inc is a supplier offers 71 products (APIs, Excipients or Intermediates).

    Find a price of Pentetreotide bulk with DMF, JDMF offered by AveXis Inc

    Find a price of Valsartan bulk with DMF, CEP offered by AveXis Inc

    Find a price of Amlodipine Besylate bulk with CEP offered by AveXis Inc

    Find a price of Baclofen bulk with DMF offered by AveXis Inc

    Find a price of Cefepime Hydrochloride bulk with JDMF offered by AveXis Inc

    Find a price of Ceftriaxone bulk with JDMF offered by AveXis Inc

    Find a price of Cyclosporine bulk with JDMF offered by AveXis Inc

    Find a price of Fluvastatin bulk with DMF offered by AveXis Inc

    Find a price of Glycolide - lactide copolymer bulk with DMF offered by AveXis Inc

    Find a price of Letrozole bulk with CEP offered by AveXis Inc

    Find a price of NAFTIFINE HCL bulk with DMF offered by AveXis Inc

    Find a price of Penicillin G Benzathine bulk with JDMF offered by AveXis Inc

    Find a price of Terbinafine bulk with DMF offered by AveXis Inc

    Find a price of Topotecan Hydrochloride bulk with DMF offered by AveXis Inc

    Find a price of Benzonatate bulk offered by AveXis Inc

    Find a price of Bisoctrizole bulk offered by AveXis Inc

    Find a price of Chlorthalidone bulk offered by AveXis Inc

    Find a price of Clofazimine bulk offered by AveXis Inc

    Find a price of Clomipramine Hydrochloride bulk offered by AveXis Inc

    Find a price of Edotreotide bulk offered by AveXis Inc

    Find a price of Eudragit Rs bulk offered by AveXis Inc

    Find a price of Methylphenidate Hydrochloride bulk offered by AveXis Inc

    Find a price of Naphazoline Hydrochloride bulk offered by AveXis Inc

    Find a price of Pyrilamine bulk offered by AveXis Inc

    Find a price of Pyrilamine Maleate bulk offered by AveXis Inc

    Find a price of Rifampicin bulk offered by AveXis Inc

    Find a price of Thurfyl Nicotinate bulk offered by AveXis Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GRIMSBY, UK bulk offered by AveXis Inc

    Find a price of ADJUVANT CGP 11637:TOXICITY STUDIES & RESULTS CONDUCTED IN EUROPEAN FA bulk offered by AveXis Inc

    Find a price of PULMONARY DRUG DELIVERY SYSTEM (PDDS) CLINICAL bulk offered by AveXis Inc

    Find a price of TINUVIN 326 bulk offered by AveXis Inc

    Find a price of FACILITY AND OPERATING PROCEDURES IN DORVAL, QUEBEC, CANADA bulk offered by AveXis Inc

    Find a price of STARTING MATERIALS 1 & 3, IN NEW JERSEY AND SWITZERLAND bulk offered by AveXis Inc

    Find a price of CGP LL637 ADJUVANT--CHEMISTRY & GMP bulk offered by AveXis Inc

    Find a price of PULMOSPHERE(R) PLACEBO INHALATION POWDER bulk offered by AveXis Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN STEIN, SWITZERLAND. bulk offered by AveXis Inc

    Find a price of TESSALON DRUG SUBSTANCE bulk offered by AveXis Inc

    Find a price of CGP 17,582B bulk offered by AveXis Inc

    Find a price of PERSONNEL, FACILS & GEN OPERATING PROCEDURES AT EAST HANOVER, NJ. bulk offered by AveXis Inc

    Find a price of 2(2'-HYDROXY-5-METHYLPHENYL) BENZOTRIAZOLE bulk offered by AveXis Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURE IN ORLEANS-LA SOURCE, FRANCE. bulk offered by AveXis Inc

    Find a price of Alpelisib bulk offered by AveXis Inc

    Find a price of Asciminib bulk offered by AveXis Inc

    Find a price of Atorvastatin bulk offered by AveXis Inc

    Find a price of Dabrafenib Mesylate bulk offered by AveXis Inc

    Find a price of Deferasirox bulk offered by AveXis Inc

    Find a price of Diclofenac Diethylamine bulk offered by AveXis Inc

    Find a price of Everolimus bulk offered by AveXis Inc

    Find a price of Fingolimod Hydrochloride bulk offered by AveXis Inc

    Find a price of Fluvastatin Sodium bulk offered by AveXis Inc

    Find a price of Hydrochlorothiazide bulk offered by AveXis Inc

    Find a price of Indacaterol Maleate bulk offered by AveXis Inc

    Find a price of Iptacopan Hydrochloride bulk offered by AveXis Inc

    Find a price of Ketotifen Fumarate bulk offered by AveXis Inc

    Find a price of Lithium Carbonate bulk offered by AveXis Inc

    Find a price of Mycophenolate Mofetil bulk offered by AveXis Inc

    Find a price of Mycophenolate Sodium bulk offered by AveXis Inc

    Find a price of Nilotinib bulk offered by AveXis Inc

    Find a price of Osilodrostat Phosphate bulk offered by AveXis Inc

    Find a price of Oxcarbazepine bulk offered by AveXis Inc

    Find a price of Pimecrolimus bulk offered by AveXis Inc

    Find a price of Ribociclib bulk offered by AveXis Inc

    Find a price of Rivastigmine bulk offered by AveXis Inc

    Find a price of Rivastigmine Tartrate bulk offered by AveXis Inc

    Find a price of Sacubitril-Valsartan bulk offered by AveXis Inc

    Find a price of Tacrolimus bulk offered by AveXis Inc

    Find a price of Terbinafine Hydrochloride bulk offered by AveXis Inc

    Find a price of Trametinib bulk offered by AveXis Inc

    Find a price of Valsartan bulk offered by AveXis Inc

    Find a price of Vildagliptin bulk offered by AveXis Inc

    Find a price of Ashmini hydrochloride bulk offered by AveXis Inc

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search